Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Johnson & Johnson (Janssen Biotech): fully responsible for developing, commercializing, and manufacturing daratumumab and bearing all associated costs
Indications
Multiple myeloma(Approved)
Status note Company's revenue and near-term prospects substantially dependent on J&J's efforts. Issued U.S. patents covering daratumumab expire in 2029 (2021-2031 in Europe/Japan with extensions); filing flags material sales decline risk post-2029.
Epcoritamab
Approved · Active
Aliases EPKINLY
Target CD3xCD20
Partnerships AbbVie: collaboration partner responsible for manufacturing; ongoing clinical trials and post-marketing confirmatory trials
Indications
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)(Approved)
Status note Approved under accelerated approval; filing notes accelerated approval is contingent on successful completion of post-marketing confirmatory trials.
Petosemtamab
Phase 3 · Active
Target EGFR/LGR5
Partnerships Acquired via Merus acquisition
Indications
Colorectal Cancer(Phase 3)
Left-sided Colorectal Cancer(Phase 3)
Status note Added to the pipeline through the Merus acquisition, including two additional Phase III trials and two Phase II trials. Filing states the company expects to commence additional studies and continue current ongoing petosemtamab studies.
Rinatabart sesutecan
Stage not disclosed · Active
Aliases Rina-S
Target FRα
Status note Acquired recent-transaction product. Filing describes it as one of the few programs Genmab itself advanced into late-stage clinical development; commercial-launch planning referenced, but the excerpts state no explicit phase or indication. Manufacturing CMO is based in China, flagged as a U.S. government-contracting/legislative risk.
Acasunlimab
Stage not disclosed · Terminated
Indications
PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metast(Phase 3)
Non Small Cell Lung Cancer Metastatic(Phase 3)
Status note Clinical development discontinued in December 2025 per the filing.
Per-asset detail extracted from the 20-F filed 2026-02-17. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (32 as sponsor, 22 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.